Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the firm's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Royalty Pharma Stock Performance
Shares of NASDAQ:RPRX opened at $50.09 on Friday. Royalty Pharma PLC has a twelve month low of $31.97 and a twelve month high of $50.47. The firm has a market cap of $28.89 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 3.16 and a beta of 0.39. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40. The business has a fifty day moving average of $47.31 and a 200-day moving average of $42.36.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The company had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. On average, equities research analysts predict that Royalty Pharma PLC will post 5.08 EPS for the current fiscal year.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.9%. Royalty Pharma's dividend payout ratio (DPR) is 69.63%.
Institutional Trading of Royalty Pharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC increased its position in Royalty Pharma by 34.1% in the first quarter. Sequoia Financial Advisors LLC now owns 15,670 shares of the biopharmaceutical company's stock worth $752,000 after purchasing an additional 3,981 shares during the period. Hsbc Holdings PLC boosted its holdings in Royalty Pharma by 2,562.2% during the first quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company's stock worth $74,000,000 after buying an additional 1,486,020 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Royalty Pharma by 0.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,273,705 shares of the biopharmaceutical company's stock worth $61,100,000 after buying an additional 5,661 shares during the last quarter. Resona Asset Management Co. Ltd. boosted its holdings in Royalty Pharma by 3.5% during the first quarter. Resona Asset Management Co. Ltd. now owns 118,956 shares of the biopharmaceutical company's stock worth $5,706,000 after buying an additional 4,046 shares during the last quarter. Finally, R Squared Ltd bought a new position in Royalty Pharma during the first quarter worth about $736,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts recently commented on RPRX shares. UBS Group lifted their price objective on Royalty Pharma from $51.00 to $57.00 and gave the stock a "buy" rating in a research report on Tuesday, April 21st. Citigroup lifted their price objective on Royalty Pharma from $48.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, January 27th. Weiss Ratings upgraded Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, February 12th. TD Cowen reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, February 27th. Finally, Morgan Stanley lifted their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma has a consensus rating of "Buy" and a consensus target price of $50.33.
Read Our Latest Research Report on Royalty Pharma
Royalty Pharma Company Profile
(
Get Free Report)
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
